Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has secured a licensing deal with Brazilian pharmaceutical company Blanver for BIO101 (20-Hydroxyecdysone) in Latin America.
The agreement is potentially worth up to EUR108m, including an upfront payment and further additional payments if certain objectives are achieved. Biophytis is also eligible to receive double-digit royalties on net sales of BIO101 (20-Hydroxyecdysone) generated in the collaboration territory, after obtaining future marketing authorisations.
Blanver will be responsible for the registration, marketing and commercialisation of BIO 101 (20-Hydroxyecdysone) in its indications -- including obesity, respiratory infections due to COVID-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) -- upon successful completion of Biophytis' clinical trials.
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
BerGenBio partners with Tempus to advance lung cancer drug
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults